Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
25.40
0.00 (0.00%)
At close: Jun 18, 2025, 4:00 PM
25.58
+0.18 (0.71%)
Pre-market: Jun 20, 2025, 7:48 AM EDT
Moderna Revenue
Moderna had revenue of $108.00M in the quarter ending March 31, 2025, a decrease of -35.33%. This brings the company's revenue in the last twelve months to $3.18B, down -38.35% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.18B
Revenue Growth
-38.35%
P/S Ratio
3.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
MRNA News
- 3 days ago - Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript - Seeking Alpha
- 6 days ago - Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - Reuters
- 7 days ago - US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults - Reuters
- 7 days ago - Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Accesswire
- 8 days ago - Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 9 days ago - Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - Accesswire
- 9 days ago - RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say - CNBC